The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment by Rolny, Charlotte et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
ARTICLE
© 2008 Rolny et al.
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 205 No. 5  1155-1171  www.jem.org/cgi/doi/
1155
10.1084/jem.20072509
        Semaphorins are a highly conserved family of 
molecular signals originally identifi  ed as guid-
ance cues for axon navigation in neural develop-
ment (  1, 2  ). Moreover, several semaphorins 
have been implicated in angiogenesis, immune 
function, and cancer (for reviews see refer-
ences   3, 4  ). 
  The functional role of semaphorins in tumor 
progression is still controversial. For example, 
semaphorin 3B (  SEMA3B  ) and the homologous 
gene   SEMA3F   have been indicated as puta-
tive tumor suppressors because they are both 
located in the chromosomal region 3p21.3, a 
locus frequently deleted or hypermethylated 
in lung cancers (  5, 6  ). SEMA3B and SEMA3F 
can further  more inhibit tumor proliferation 
in vitro and in vivo (  7  –  9  ) Moreover, SEMA3F 
has been shown to inhibit angiogenesis and 
metastatic dissemination (  10, 11  ). 
  We have previously demonstrated that 
semaphorin function is mediated by a family 
of plasma membrane receptors, the plexins (  12  ). 
However, most secreted semaphorins (including 
SEMA3B) do not bind directly to plexins but 
instead interact with plexin-associated corecep-
tors, denoted neuropilin (NP) 1 and 2. More-
over, NPs directly bind vascular endothelial 
growth factor (VEGF) family members and as-
sociate in complex with VEGF receptors (  13  ), 
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  Semaphorins are a large family of evolutionarily conserved morphogenetic molecules 
originally identifi  ed for their repelling role in axonal guidance. Intriguingly, semaphorins 
have recently been implicated in cancer progression (Neufeld, G., T. Lange, A. Varshavsky, 
and O. Kessler. 2007.   Adv. Exp. Med. Biol.   600:118  –  131). In particular, semaphorin 3B 
(SEMA3B) is considered a putative tumor suppressor, and yet we found that it is ex-
pressed at high levels in many invasive and metastatic human cancers. By investigating 
experimental tumor models, we confi  rmed that SEMA3B expression inhibited tumor 
growth, whereas metastatic dissemination was surprisingly increased. We found that 
SEMA3B induced the production of interleukin (IL) 8 by tumor cells by activating the 
p38  –  mitogen-activated protein kinase pathway in a neuropilin 1  –  dependent manner. 
Silencing the expression of endogenous SEMA3B in tumor cells impaired IL-8 transcrip-
tion. The release of IL-8, in turn, induced the recruitment of tumor-associated macro-
phages and metastatic dissemination to the lung, which could be rescued by blocking IL-8 
with neutralizing antibodies. In conclusion, we report that SEMA3B exerts unexpected 
functions in cancer progression by fostering a prometastatic environment through 
elevated IL-8 secretion and recruitment of macrophages coupled to the suppression 
of tumor growth. 1156 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
    RESULTS   
  SEMA3B is commonly expressed in human cancer cells 
  Previous studies (  5  –  9  ) have indicated SEMA3B as a putative 
tumor suppressor whose expression may be lost in cancer 
cells. Surprisingly, in a screen of   >  25 human tumor-derived 
cell lines, we found signifi   cantly high levels of SEMA3B 
mRNA in cells derived from diff  erent kinds of tumors, in-
cluding some of metastatic origin such as colon carcinoma 
(LoVo), mammary carcinoma (SKBR-3), and melanomas 
(Sk-Mel-2 and MALME-3M;   Fig. 1 A  ).   We confi  rmed the 
expression of SEMA3B receptors NP1 and 2, as well as mul-
tiple plexins, in these cells (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20072509/DC1; and not de-
picted); however, we did not observe any signifi  cant (direct 
or inverse) correlation between SEMA3B expression and that 
of potential receptors in tumor cells. To investigate further a 
putative correlation between SEMA3B expression and tumor 
progression, we analyzed three distinct datasets derived from 
microarray gene expression profi  ling in breast cancers (  16  ), 
lung cancers (  17  ), and malignant melanomas (  18  ). Surprisingly, 
we could not observe any direct correlation between low 
SEMA3B expression and poor patient survival; instead, high 
levels of SEMA3B seemed to associate with metastatic pro-
gression in a subset of lung carcinomas (P = 0.0062; Fig. S2 C). 
Importantly, malignant melanomas were found to express strik-
ingly high levels of SEMA3B compared with benign nevi (P = 
2.5   ×   10      11  ;   Fig. 1 B  ). This is consistent with our fi  nding that 
established melanoma cell lines express high SEMA3B levels 
(e.g., Sk-Mel-2, MALME-3M, and UACC-257 in Fig. S1 A). 
playing a crucial role in angiogenesis beyond axon guidance 
(for review see reference   14  ). SEMA3B interacts with both 
NP1 and NP2, whereas little is known about the require-
ment of specifi  c plexins in the receptor complex. In general, 
diff  erent plexins of the A subfamily seem to be functionally 
redundant in mediating semaphorin signaling in association 
with the NPs. 
  Interestingly, SEMA3B has been shown to exert dual 
functions in the guidance of cortical axons, acting either as 
an attractant or a repellant on diverse neuronal populations 
(  15  ). This fi  nding is consistent with that reported for other 
family members and suggests that semaphorins may have 
antagonistic functions, depending on the target cells. This 
is particularly important in cancer biology, because tumors 
are known to be multifaceted tissues comprising several regu-
latory cells, in addition to tumor cells. Intriguingly, although 
previous experiments have analyzed SEMA3B activity on 
tumor cell proliferations, its potential eff  ects on metastatic 
dissemination have not been addressed. We report that al-
though expression of SEMA3B in tumor cells may delay tu-
mor growth, it also promotes metastatic dissemination. Our 
data indicate that this activity of SEMA3B is mediated by 
NP1-dependent activation of p38  –  mitogen-activated protein 
kinase (MAPK), leading to the induction of p21 growth-
inhibitory protein, as well as of the prometastatic cytokine 
IL-8. Moreover, we found that IL-8 activity is required to 
mediate the recruitment of tumor-associated macrophages 
(TAMs) and metastatic dissemination in SEMA3B-express-
ing tumors. 
    Figure 1.         SEMA3B is signifi  cantly expressed in human cancers.   (A) SEMA3B expression levels were measured by real-time PCR in 26 different hu-
man tumor cell lines, including colorectal carcinomas (HT-29, LoVo, SV80, HCT 116, and Difi  ), breast adenocarcinomas (SK-BR3, MDA-MB231, and T47D), 
osteosarcoma cells (U2OS, KHOS-NP, Saos-2, and MG-63), prostate adenocarcinomas (PC-3 and DU145), and melanomas (Sk-Mel-2, UACC-257, MALME-
3M, and MDA-MB435; reference   20  ), as well as gastric carcinoma (GTL-16), hepatocellular carcinoma (HepG2), cervical adenocarcinoma (HeLa), chronic 
myelogenous leukemia (K-562), pancreatic cancer (SUIT-2), histiocytic lymphoma (U-937), neuroblastoma (IMR5), and nonsmall-cell lung carcinoma 
(A549). A Taqman probe for human     -actin   was used as the internal control for each sample. SEMA3B expression levels in cancer cells were then normal-
ized to the mean (REF = 1; dashed line) of values obtained in three different nontumor immortalized cell lines (mammary epithelial cells [MCF-10A], 
mesothelial cells [Met-5A], and retinal pigmented epithelium [RPE]). Data are reported as the mean   ±   SD of triplicates. The y axis is broken to include 
representation of high value data points. (B) SEMA3B expression in 45 individual samples of malignant melanoma and 18 samples of benign nevi. 
Reported values indicate normalized SEMA3B detection signals derived from a microarray dataset previously described by Talantov et al. (reference   18  ). 
The dashed line indicates the threshold of detection call. None of the nonmalignant samples expressed SEMA3B above the detection confi  dence threshold, 
whereas semaphorin expression is high in most melanoma samples (P = 2.5   ×   10     11 ).   JEM VOL. 205, May 12, 2008 
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    Figure 2.         SEMA3B-expressing tumors display reduced growth but increased metastatic dissemination.   (A) MDA-MB435 (MDA) and A549 cells trans-
duced to express SEMA3B (3B) or a noncoding EV were grown in culture for 4 d in 1% FBS. Cell growth was evaluated daily in separate dishes by staining cells 
with crystal violet and measuring absorbance. Data shown represent the mean and SD of triplicates.(B and C) SEMA3B-transduced and EV control tumor cells 
were injected subcutaneously into nude mice. Graphs display tumor volume (measured externally during the experiment; B) and tumor weight (measured after 
excision at the end of the experiment; C), respectively. Data shown are the mean   ±   SEM from nine mice per each experimental group. ***, P   <   0.0005. (D) The 
expression of SEMA3B (Myc tagged) was detected in tumors by staining tissue sections with anti-Myc antibodies (green), whereas nuclear counterstaining was 
done with DAPI (blue). Bar, 100   μ  m. SEMA3B was similarly detected in tumor lysates by Western blotting (bottom). (E) At the end of the experiment, the lungs of 
mice carrying tumor xenografts (as described above) were contrasted by airway perfusion with India ink, and superfi  cial metastases were counted under a ste-
reoscopic microscope. Numbers of metastases are given as the mean   ±   SD from nine mice for each experimental group (left). We further determined the meta-
static index of SEMA3B-expressing and control tumors (right) by calculating the ratio between the number of metastatic foci and tumor weight. **, P   <   0.01; ***, 
P   <   0.001. (F) A549 cells expressing SEMA3B under control of a doxycycline-inducible promoter were injected subcutaneously in nude mice. Tumor cells express-
ing the transactivator rTTA alone were used as controls. After 46 d, the mice were killed, and we measured tumor burden, counted lung metastasis, and calculated 
the metastatic index as described. Data shown are the mean   ±   SEM. Western blot analysis on protein lysates from tumor samples (top) revealed a minimum level 
of recombinant SEMA3B expression in the absence of the doxycycline, which was strongly induced by treatment with the drug. *, P   <   0.05; **, P   <   0.01.    1158 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
inducible promoter in A549 cells. This system allowed us to 
obtain drug-regulated expression of SEMA3B in tumor xe-
nografts in vivo. Notably, low levels of SEMA3B were de-
tected in tumors in the absence of the drug, whereas they 
greatly increased upon treatment with doxycycline (  Fig. 2 F  , 
top). Semaphorin levels in xenografts correlated directly with 
the metastatic potential and inversely with the tumor burden 
(  Fig. 2 F  , bottom). 
  Tumor cell proliferation and angiogenesis in 
SEMA3B-expressing tumors 
  We hypothesized that the inhibition of tumor growth by 
SEMA3B could be accounted for by a primary eff  ect on cell 
proliferation, consistent with our data in vitro. To reliably 
answer this question, we analyzed tumors of comparable size 
taken 15 d after transplant. Consistent with in vitro observa-
tions, SEMA3B-expressing tumor cells showed a   >  60% re-
duction in proliferation rate when transplanted in vivo (as 
assessed by anti  –  human Ki-67 staining;   Fig. 3 A  ), whereas 
apoptosis was only moderately increased (detected by Tdt-
mediated dUTP-biotin nick-end labeling [TUNEL];   Fig. 3 B  ); 
these results were further confi  rmed by analyzing tumors at a 
later stage (30 d; not depicted).   Double-staining experiments 
with markers of endothelia and TAMs did not detect a sig-
nifi  cant number of mouse stromal cells undergoing apoptosis 
(unpublished data), consistent with those that were essentially 
represented by tumor cells. Because it has been shown pre-
viously that other semaphorins can inhibit VEGF-induced 
angiogenesis (for review see reference   21  ), we asked whether 
SEMA3B could similarly mediate inhibition of tumor angio-
genesis. We could not fi  nd any signifi  cant diff  erence in vessel 
area, as measured by lectin-perfused vessels, between SEMA3B 
xenografts and controls in tumors of comparable size (15 d 
after transplant); notably, the number of vessels was slightly 
increased in SEMA3B-expressing xenografts compared with 
controls, suggesting that vessel structure was altered (  Fig. 3, 
C and D  ). However reduced angiogenesis was unlikely to 
be primarily responsible for delayed tumor growth. We ob-
served a 25% reduction of angiogenesis in tumors expressing 
SEMA3B at later stages (day 30), when they had become re-
markably smaller than controls (unpublished data). Moreover, 
in SEMA3B-expressing tumors, we observed notable defects 
of pericyte recruitment to blood vessels compared with con-
trol xenografts (  Fig. 3 E  ). 
  Macrophage recruitment in SEMA3B tumors 
  Several important factors regulating tumor angiogenesis and 
metastatic dissemination are released by TAMs (  22  –  24  ). In-
terestingly, by staining our cryostat sections with the selective 
antibody F4/80 for macrophages, we observed a twofold in-
duction of macrophage recruitment into the tumor periphery 
(  Fig. 4 A  , top row) in SEMA3B xenografts, as well as an in-
creased infi  ltration in the center of the tumor (  Fig. 4 A  , bot-
tom row).   In contrast, tumor-infi  ltrating granulocytes did not 
increase upon SEMA3B expression in vivo (based on Gr1 
immunostaining; unpublished data). 
Moreover, Hoek et al. reported a sixfold induction of SEMA3B 
gene expression in primary malignant melanoma cells com-
pared with normal melanocytes (  19  ). 
  These fi  ndings seemed to challenge the idea that SEMA3B 
functions as a tumor suppressor and prompted us to experi-
mentally test in vivo the functional role of SEMA3B in can-
cer progression and metastasis. For our experiments, we thus 
selected MDA-MB435 human tumor cells (of melanoma ori-
gin) (  20  ), which are characterized by very low expression of 
SEMA3B (  Fig. 1 A  ), a fast growth rate, and low metastatic 
potential, and A549 nonsmall-cell lung carcinoma cells that 
express intermediate levels of SEMA3B and form slowly 
growing metastatic tumors in nude mice. 
  SEMA3B inhibits tumor growth but induces metastasis in vivo 
  We transduced MDA-MB435 and A549 cells with lentiviral 
vectors either encoding SEMA3B or a noncoding empty vec-
tor (EV). SEMA3B-transduced cells did not undergo any clear 
morphological change compared with controls (unpublished 
data). Consistent with what has been previously shown in other 
tumor cell lines (  7  –  9  ), we observed growth inhibition in MDA-
MB435 and A549 cells upon SEMA3B expression (  Fig. 2 A  ).   
Moreover, in accordance with previous data on MDA-MB435 
cells (  9  ), we found that NP1 receptor expressed in tumor cells 
was likely implicated to mediate this autocrine eff  ect, because 
NP1-blocking antibodies could rescue SEMA3B-induced 
growth inhibition, whereas RNA interference (RNAi)  –  me-
diated suppression of NP2 could not (Fig. S3, available at 
http://www.jem.org/cgi/content/full/jem.20072509/DC1). 
Notably, we found no evidence of increased cell apoptosis in 
vitro upon SEMA3B expression, nor that SEMA3B expression 
signifi  cantly aff  ected tumor cell motility or cell scattering in 
vitro (unpublished data). 
  The tumorigenic potential of SEMA3B-expressing cells 
was analyzed in vivo by subcutaneous transplantation in nude 
mice. Tumor volume was periodically measured, and tumor 
weight was determined upon dissection at the end of the ex-
periment. Tumor xenografts expressing SEMA3B displayed 
a signifi  cant reduction in volume and tumor burden (  Fig. 2, 
B and C  ), yet they were surprisingly associated with a remark-
able increase of spontaneous metastatic dissemination to the 
lungs (  Fig. 2 E  ). The metastatic potential was quantifi  ed by 
scoring macrometastasis in the lungs (  Fig. 2 E  , left). Moreover, 
we found that the ratio between the number of metastatic foci 
and the size of respective primary tumors was increased   >  10 
times in SEMA3B-expressing tumors versus controls (  Fig. 2 
E  , right), indicating a strong increase in the metastatic poten-
tial of tumor cells. SEMA3B expression was confi  rmed in pri-
mary tumors by the immunostaining of cryostat sections (  Fig. 
2 D  , top) and by Western blot analysis of protein lysates from 
tumor samples (  Fig. 2 D  , bottom). SEMA3B expression was 
also detected in metastatic cells by immunostaining (unpub-
lished data), ruling out that they represented a selected sub-
population of cells that have lost SEMA3B expression. 
  To confi  rm the specifi  city of these eff  ects, we expressed 
SEMA3B under the control of an rTTA- and doxycycline-JEM VOL. 205, May 12, 2008 
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  These fi  ndings indicated that SEMA3B expression in tumor 
cells induces their ability to attract monocytes/macrophages. 
To further investigate this eff  ect, we performed migration 
assays in vitro with monocytes purifi  ed from human periph-
eral blood. As shown in   Fig. 4 B  , the conditioned medium 
(CM) of MDA-3B cells strongly attracted monocytes in a dose-
dependent manner compared with the medium collected 
from mock-transduced control cells. The eff  ect was compa-
rable to that induced by the well-known monocyte chemo-
tactic protein 1 (MCP-1;   Fig. 4 B  ). Intriguingly, monocyte 
chemotaxis was not aff  ected by immunodepleting SEMA3B 
content in the CM (unpublished data), suggesting that the 
semaphorin had induced the release of further regulatory fac-
tors by tumor cells. 
    Figure 3.         Tumor cell proliferation and angiogenesis in SEMA3B-expressing tumors.   (A) Control or SEMA3B-expressing tumors (15 d after transplant) 
were immunostained to reveal KI-67 proliferation markers (red), whereas nuclei were visualized by DAPI (blue). Representative fi  elds are shown. Bar, 20   μ  m. 
The bar graph shows the percentage of Ki-67  –  positive cells (mean   ±   SD) in six tumors per each experimental group. For all quantifi  cations shown in this fi  g-
ure, at least three sections and 10 fi  elds were counted for each tumor. **, P   <   0.01. (B) Tumor sections were analyzed to reveal apoptotic cells using TUNEL 
green kit. Micrographs show representative fi  elds. Bars, 20   μ  m. The bar graph indicates the percentage of TUNEL-positive cells (mean   ±   SD) in six tumors per 
each experimental group. (C) Micrographs show sections from tumors stained with SA-lectin to reveal endothelial cells (red), whereas nuclei were marked 
with DAPI (blue). Bar, 60   μ  m. (D) Quantifi  cation of the results in C. The graphs indicate the percent area occupied by vessels (left) or the vessel number (right), 
calculated in six fi  elds per section. Values represent the mean   ±   SD from six tumors per each experimental group. *, P   <   0.05. (E) Sections from tumors excised 
at day 21 after transplant were immunostained with anti-CD31 (red) and with an antibody revealing the chondroitin proteoglycan NG2 that is expressed on 
pericytes (green). Micrographs show representative fi  elds at low and high magnifi  cations (left and right, respectively). Bars: (left) 60   μ  m; (right) 20   μ  m.    1160 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
lated by treatment with doxycycline in A549 carcinoma cells 
expressing SEMA3B under the control of a drug-inducible 
promoter (  Fig. 5 D  ). 
  Monocyte/macrophage recruitment induced by SEMA3B 
depends on IL-8 
  Consistent with previous reports (  28  –  30  ), we observed a 
signifi  cant dose-dependent increase of monocyte migration 
in vitro in response to purifi  ed IL-8 (Fig. S4 A, available at 
http://www.jem.org/cgi/content/full/jem.20072509/DC1). 
This monocyte-attracting activity of purifi  ed IL-8 was com-
parable to that induced by the CM of SEMA3B-expressing 
cells (Fig. S4 A); moreover, it was effi   ciently blocked by mono-
clonal anti  –  IL-8 neutralizing antibodies (MAB208; Fig. S4 B). 
Therefore, to test whether monocyte recruitment induced 
by SEMA3B-CM could actually depend on increased IL-8 
  SEMA3B induces IL-8 expression in tumor cells 
  By performing microarray analysis of gene expression on 
mRNA derived from MDA-MB435 cells transduced with 
SEMA3B or EV, we found that the most signifi  cantly regu-
lated gene was IL-8 (P   <   0.001;   Fig. 5 A  ).   Interestingly, IL-8 
is known to be a chemoattractant for leucocytes and endo-
thelial and smooth muscle cells, which are further implicated 
in human cancer biology (  25  –  27  ). 
  We thus confi  rmed microarray data by real-time quanti-
tative PCR in tumor cell lines transduced with SEMA3B 
(i.e., A549 lung carcinoma, HeLa cervical carcinoma, HT29 
colon carcinoma, and GTL16 gastric carcinoma;   Fig. 5 B  ). In 
addition, the CM of MDA-3B and control cells was collected 
and analyzed by Western blotting, revealing that IL-8 secre-
tion was strongly induced upon SEMA3B expression (  Fig. 
5 C  ). Moreover, IL-8 protein levels were specifi  cally up-regu-
    Figure 4.         SEMA3B expression in tumor cells induces macrophage recruitment.   (A) Sections from tumors excised at day 15 after transplant were 
immunostained with anti-F4/80 antibody to selectively detect macrophages (red), whereas nuclei were revealed with DAPI (blue). Macrophages were 
quantifi  ed in the periphery and in the center of the tumors. Bars, 60   μ  m. The graphs represent the mean   ±   SD from eight tumors for each experimental 
group (at least three sections and 10 fi  elds occupied by macrophages were counted from each tumor). ***, P   <   0.001; **, P   <   0.01. (B) The migration of 
monocytes purifi  ed from human peripheral blood was analyzed in a Transwell migration assay. Increasing concentrations of CM (1x, 3x, or 10x, as indi-
cated) derived from tumor cells transduced with SEMA3B (3B) or EV were included in the lower chamber (or alternatively in the upper chamber, as speci-
fi  ed). Migrated monocytes were stained with Giemsa and counted in low magnifi  cation micrographs of the fi  lters, as reported previously (reference   27  ). 
Values in the graph represent the mean   ±   SD of three independent experiments. 100 ng/ml MCP-1 in the lower chamber provided an internal positive 
control. n.t., nontreated cells.     JEM VOL. 205, May 12, 2008 
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knock down of SEMA3B expression led to reduced levels of 
IL-8 mRNA (  Fig. 6 A  ).   Furthermore, three diff  erent shRNA 
sequences for SEMA3B were tested with consistent results, 
ruling out off  -target eff  ects (Fig. S5, available at http://www
.jem.org/cgi/content/full/jem.20072509/DC1). 
  To investigate the role of endogenous SEMA3B in mono-
cyte recruitment by tumor cells, we performed migration assays 
with the CM of Sk-Mel-2 melanoma cells that basally se-
crete high levels of IL-8 (unpublished data). The medium 
collected from control cells strongly attracted monocytes 
compared with that of SEMA3B-defi  cient cells (shSEMA3B; 
  Fig. 6 B  ). Importantly, this functional diff  erence was entirely 
accounted for by the loss of IL-8 expression in shSEMA3B 
cells, because including IL-8 neutralizing antibodies abro-
gated the diff  erence between monocyte migration induced 
by control CM and that of SEMA3B-defi  cient melanoma 
cells (  Fig. 6 B  ). 
secretion by tumor cells, we repeated migration assays, as in 
  Fig. 4 B  , in the presence of anti  –  IL-8 neutralizing antibodies. 
  Fig. 5 E   shows that this treatment abolished the functional 
diff  erence between the chemotactic activities of SEMA3B-
CM and control EV-CM, whereas an irrelevant antibody (    -
CD19) was ineff  ective. These data clearly indicated that the 
cytokine IL-8, released by tumor cells in response to an auto-
crine loop of SEMA3B, was crucially implicated to increase 
monocyte recruitment. 
  Consistent with our evidence that SEMA3B regulates 
IL-8 production, we asked whether IL-8 levels might be af-
fected upon knocking down endogenous SEMA3B in cancer 
cells. We thus stably transduced various tumor cells expressing 
medium to high levels of SEMA3B (i.e., A549, HeLa, LoVo, 
and Sk-Mel-2 cells) with constructs expressing short hairpin 
RNAs (shRNAs) targeting SEMA3B (shSEMA3B) or control 
unrelated sequences (shCTR). Importantly, we found that the 
    Figure 5.         SEMA3B induces IL-8 expression in tumor cells, which accounts for increased monocyte attraction.   (A) mRNA from transduced 
MDA-MB435 cells was used to probe a microarray representative of the human genome. Results are shown as a dot plot of individual genes, compar-
ing the expression levels found in EV  –   and SEMA3B-transduced cells. A selected panel of 622 genes, including cytokines and factors mediating infl  am-
matory response (identifi  ed by keywords as described in Materials and methods), is highlighted in red.   IL-8   is the only gene in the panel signifi  cantly 
regulated more than twofold. ***, P   <   0.001) (B) Real-time quantitative PCR mRNA expression analysis of SEMA3B- and EV-transduced tumor cells us-
ing Taqman probes for IL-8 and for the housekeeping gene     -actin   (internal reference). Reported values indicate fold induction of IL-8 expression in 
SEMA3B-expressing cells relative to the respective EV control for each cell line, and values correspond to the mean   ±   SD of three individual experi-
ments. *, P   <   0.05. (C) The CM from MDA-MB435 EV control and SEMA3B-expressing cells was collected and concentrated 300 times. 10   μ  l of this prep-
aration was analyzed by Western blotting with anti  –  IL-8 antibodies. The indicated amounts of purifi  ed IL-8 were loaded for internal reference. The 
concentration of IL-8 in the original CM of MDA-3B cells was thus estimated to be in the range of 5  –  7 ng/ml. (D) Western blot analysis of A549 cells 
expressing SEMA3B under a drug-inducible promoter; control cells (EV) expressed the doxycycline-dependent transactivator rTTA alone. Upon doxycy-
cline treatment, SEMA3B expression in tumor cells (revealed by anti-Myc tag antibodies) and IL-8 levels in the CM (revealed with MAB208) were in-
creased; purifi  ed IL8 was loaded as an internal reference. (E) The CM of SEMA3B tumor cells and EV controls were assayed in monocyte migration 
experiments, similar to those shown in   Fig. 4 B  . Where indicated, IL-8 neutralizing antibodies (MAB208) or an unrelated control antibody (i.e., anti-
CD19; C Ab), or 100 ng/ml of purifi  ed IL-8 were added in the lower well. The number of migrated monocytes was scored as in   Fig. 4 B  , and the graph 
shows the mean of three independent experiments. IL-8 is responsible for the increased monocyte-attracting activity released by SEMA3B-expressing 
tumor cells. **, P   <   0.01.     1162 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
residual macrophage infi  ltration (  Fig. 7, D and E  ). In con-
trast, there was no signifi  cant reduction in control tumors. 
These fi  ndings suggested a putative antiangiogenic activity of 
SEMA3B, masked in vivo by increased IL-8 release. Notably, 
other class 3 semaphorins have been shown to repel endo-
thelial cells and to inhibit angiogenesis both in vitro and in 
vivo (  10, 36  ). In fact, we could demonstrate a repelling activ-
ity of SEMA3B on human umbilical vein endothelial cells 
(HUVECs) in co-culture experiments and migration assays 
in vitro, even if this inhibitory eff  ect was partly mitigated by 
the autocrine secretion of IL-8 induced by the semaphorin 
(Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20072509/DC1). Consistent with the reduced vascular-
ization in SEMA3B-expressing tumors treated with MAB208, 
we also found a fourfold induction of apoptosis (  Fig. 7 F  ), 
whereas tumors in all other conditions were not signifi  cantly 
aff  ected. Importantly, we ruled out any direct detrimental ef-
fect of the antibody on the viability or proliferation of tumor 
cells by further examining the growth rate in the absence or 
presence of MAB208 in vitro (unpublished data). 
  SEMA3B-dependent IL-8 induction is mediated by NP1 
and p38  –  MAPK activation 
  In an eff   ort to identify the molecular mechanisms driving 
SEMA3B-dependent IL-8 induction in tumor cells, we inves-
tigated NF-    B and p38  –  MAPK, two known regulators of IL-8 
expression at transcriptional and posttranscriptional levels 
(  25  ). The nuclear translocation of NF-    B was not signifi  cantly 
increased in MDA-3B cells (unpublished data). However, 
SEMA3B-expressing cells displayed a striking increase in p38 
phosphorylation upon serum starvation compared with con-
trols (  Fig. 8 A  ).   Moreover, by treating MDA-MB435 or A549 
cells with CM containing SEMA3B, we rapidly induced the 
phosphorylation of p38 and its major substrate, activating tran-
scription factor 2 (ATF-2), whereas MAPK phosphorylation 
was not induced (  Fig. 8, B and C  ). To investigate the require-
ment of p38  –  MAPK signaling for SEMA3B-dependent IL-8 
induction, we cultured transduced cells in the presence of se-
lective p38 inhibitors. As shown in   Fig. 8 D  , blocking p38 sig-
naling abrogated IL-8 expression in SEMA3B-expressing cells. 
  It has been previously described that p38 regulates the 
expression of the cytokine-dependent kinase inhibitor (CDKI) 
p21-Waf (  37  ). We therefore investigated p21 protein levels in 
SEMA3B-transduced cells and found that they were increased 
compared with controls (staurosporin was used as a positive 
control for p21 induction;   Fig. 8 E  ). Because we had found 
that NP1 is required for SEMA3B-dependent growth in-
hibition (Fig. S3 A), we asked whether the same receptor was 
involved in SEMA3B-induced p38  –  MAPK activation. In fact, 
by incubating cells with anti-NP1 blocking antibodies, we 
demonstrated that the activation of this pathway requires NP1 
(  Fig. 8 F  ). Furthermore we exploited RNAi to knock down 
NP1 in tumor cells. Interestingly, SEMA3B overexpression in 
NP1-defi  cient cells could not up-regulate IL-8 levels (  Fig. 8 G  ), 
indicating that the signaling pathway depends on this   receptor. 
In contrast, RNAi-mediated knock down of NP2 did not 
  IL-8 mediates macrophage infi  ltration and metastasis 
in SEMA3B-expressing tumors 
  Elevated IL-8 expression in tumors is a poor prognostic indi-
cator correlating with invasive/metastatic progression (  31  –  33  ); 
thus, we hypothesized that this cytokine could account for 
the metastatic progression observed in SEMA3B-expressing 
tumors. To this end, we exploited neutralizing antibodies 
(MAB208) to inhibit IL-8 function in vivo, as successfully 
done in previous studies (  34, 35  ). MDA-EV and MDA-3B 
tumor xenografts were treated with MAB208 or with an ir-
relevant control antibody from the same day of transplant and 
twice a week for a period of 2 wk by direct injection at the 
tumor site. Tumor volume was not signifi  cantly altered by 
MAB208 treatment (  Fig. 7 A  ).   In contrast, the increased re-
cruitment of macrophages into tumors and the metastatic dis-
semination induced by SEMA3B were totally prevented by 
MAB208 (  Fig. 7, C and B  , respectively), whereas tumors treated 
with control antibody were not aff  ected. Moreover, tumor 
angiogenesis in SEMA3B-expressing tumors was strongly 
reduced upon MAB208 treatment and associated with sites of 
    Figure 6.         SEMA3B knock down in tumor cells affects IL-8 produc-
tion and monocyte recruitment.   (A) RNA was collected from LoVo, 
A549, HeLa, and Sk-Mel-2 cells transduced with shRNA against SEMA3B 
(to suppress gene expression; shSEMA3B) and unrelated sequences 
(shCTR). Real-time PCR was performed using Taqman probes for SEMA3B 
(results shown at the bottom) and IL-8 (in the graph). Expression levels 
were normalized to controls for each cell line and are represented as fold 
changes. Data shown are the mean   ±   SEM. (B) Monocyte migration to CM 
derived from Sk-Mel-2 melanoma cells transduced with shRNAs. IL-8 
neutralizing antibodies (MAB208) or unrelated control antibodies (anti-
CD19) were included in the lower chamber. Knock down of SEMA3B ex-
pression in Sk-Mel-2 cells abolished IL-8  –  dependent monocyte-attracting 
activity in the CM. The number of migrated monocytes represents the 
mean   ±   SEM of two independent experiments. **, P   <   0.01.     JEM VOL. 205, May 12, 2008 
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    DISCUSSION   
  Semaphorins, beyond their well-characterized function in 
neuronal guidance, have also been implicated in tumorigene-
sis. In particular,   SEMA3B   is considered a putative tumor 
  aff  ect SEMA3B-dependent IL-8 induction (unpublished data). 
Thus, the NP1 receptor and p38  –  MAPK signaling are required 
in the pathway mediating SEMA3B-dependent growth in-
hibition and IL-8 up-regulation. 
    Figure 7.         Neutralizing IL-8 in SEMA3B-expressing tumors blocks macrophage recruitment and metastasis.   (A) Nude mice were injected subcu-
taneously with either MDA-EV or MDA-3B tumor cells together with 100   μ  g of neutralizing IL-8 antibody (MAB208) or 100   μ  g of control antibody (anti-
CD19). Antibodies were administered locally into tumors again at days 2, 5, 8, and 11 after tumor transplant. Data shown are the mean tumor volume   ±   
SD from 10 tumors per each experimental group at the day of excision (day 15). (B) To reveal metastatic dissemination from the tumors, the lungs of mice 
described in A were analyzed by real-time RT-PCR using species-specifi  c Taqman probes for mouse HPRT and human HPRT transcripts. Plotted values 
indicate the mean ratio between human and mouse RNA levels in the lungs of fi  ve mice per each experimental group   ±   SD. *, P   <   0.05. (C) Tissue sections 
from SEMA3B and EV tumors, treated with control antibody or MAB208 (from the same experiment as in A), were stained with anti-F4/80 to detect mon-
ocytes/macrophages (red), whereas nuclei were revealed with DAPI (blue). Bar, 60   μ  m. Each data point represents the mean percentage of the macro-
phage-occupied area   ±   SD from eight tumors per each experimental group (10 fi  elds were counted from at least three different sections for each tumor). 
**, P   <   0.01; ***, P   <   0.001. (D) Blood vessels and macrophages in sections of MDA-EV or MDA-3B tumors treated as described were revealed with anti  –  VE-
cadherin (red) and anti-F4/80 (green); nuclei were marked with DAPI. Bar, 60   μ  m. (E) Blood vessels in sections of MDA-EV or MDA-3B tumors treated as 
described were revealed with anti-CD31 antibody (red), whereas nuclei were marked by DAPI (blue). Bar, 60   μ  m. The graph shows the mean vessel area   ±   
SD from eight tumors for each experimental group (at least three sections and 10 fi  elds were quantifi  ed per tumor). ***, P   <   0.0005. (F) Sections from 
MDA-EV or MDA-3B tumors treated as described were subjected to TUNEL staining to reveal apoptotic cells. Bar, 60   μ  m. The graph shows the mean per-
centage of TUNEL-positive cells (  ±  SEM) from fi  ve tumors for each experimental group in at least three sections and 10 fi  elds. *, P   <   0.05.     1164 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
    Figure 8.         p38  –  MAPK signaling elicited by SEMA3B mediates IL-8 induction.   (A) Immunoblotting analysis to reveal phospho-p38 protein levels in 
MDA-MB435 tumor cells expressing SEMA3B (or EV controls), grown in the presence or absence of 10% FBS for 48 h. Results are displayed as fold induc-
tion of the phosphorylated/total p38 ratio in SEMA3B cells versus controls, as measured by densitometric analysis. (B) Serum-starved MDA-MB435 cells 
were treated for 30 min with CM collected from SEMA3B or EV control cells. The levels of phospho-p38 and phospho  –  ATF-2 were analyzed in protein 
lysates by immunoblotting. The same fi  lter was furthermore decorated to reveal vinculin, providing loading controls. Plotted values indicate fold increase 
of the phosphorylated p38/vinculin or ATF2/vinculin ratios in SEMA3B-treated cells versus controls. (C) Immunoblotting analysis of A549 cells treated as 
in B with SEMA3B or EV control CM. Filters were probed to reveal phospho-p38, phospho-p42/44  –  MAPK, and vinculin levels (as loading control). The 
graph shows fold increase of the phosphorylated p38/vinculin or phospho-p42/44  –  MAPK/vinculin ratios in SEMA3B-treated cells versus controls. 
(D) MAB208 antibody was used to detect IL-8 expression by immunofl  uorescence (top) or by Western blotting (bottom) in SEMA3B-expressing and control 
cells grown in the absence of serum for 48 h, in the presence or absence of 10   μ  M of the selective p38  –  MAPK inhibitor SB202190. Micrographs were ac-
quired with a bioimager (Pathway; BD Biosciences) and quantifi  ed by Autovision 1.5 (10 images per each data point). Results are displayed as mean   ±   SD. 
***, P   <   0.001. (E) CDKI p21 expression was detected by Western blotting in A549 cells, transduced with SEMA3B or EV control, upon serum starvation JEM VOL. 205, May 12, 2008 
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suppressor gene. In fact, consistent with previous reports (  7  –
  9  ), we observed that SEMA3B is able to inhibit the prolifera-
tion of tumor cells in vitro and delay the growth of tumor 
xenografts in nude mice (  Fig. 2, A  –  C  ). Based on these premises, 
high expression of SEMA3B in tumors may be thought to 
correlate with good patient prognosis and vice versa. How-
ever, by analyzing large datasets of human tumor samples, we 
could not fi  nd any statistically signifi  cant correlation between 
SEMA3B expression and patient survival. In contrast, our 
data indicated that subsets of tumors with elevated SEMA3B 
levels are associated with metastatic progression and poor 
prognosis. These unexpected fi  ndings prompted us to experi-
mentally test in vivo the functional role of SEMA3B in can-
cer progression, especially because previous studies had not 
investigated its potential relevance in tumor invasion and 
metastasis. Interestingly, we found that an elevated expression 
of SEMA3B in MDA-MB435 and A549 human cancer cells 
induced spontaneous metastasis from subcutaneous tumors 
in mice. This eff  ect was even more striking considering that 
SEMA3B-expressing primary tumors were remarkably smaller 
(  Fig. 2 E  ). Moreover, unlike what was described for SEMA3E 
(  38  ), tumor cells expressing SEMA3B did not show an increased 
ability to form metastatic lung colonies upon direct injection 
in the blood circulation (Fig. S7, available at http://www
.jem.org/cgi/content/full/jem.20072509/DC1), indicating 
that SEMA3B acts by promoting cancer cell dissemination 
from the primary tumor, and not by increased cell survival or 
homing from the circulation. 
  Because SEMA3B expression in tumor cells did not seem 
to aff  ect cell adhesion, cell migration, or cell scattering in vitro 
in a cell-autonomous manner (unpublished data), we postu-
lated that the increased metastatic potential observed in vivo 
may implicate regulatory cells in the tumor microenvironment. 
In fact, we found that SEMA3B expression increased the re-
cruitment of monocytes/macrophages into the tumor micro-
environment (  Fig. 4  ); notably these TAMs are well-known 
mediators of tumor invasion and metastasis (  39, 24  ). More-
over, SEMA3B expression induced the secretion of IL-8 by 
tumor cells (  Fig. 5   and   Fig. 6  ), a cytokine also associated with 
tumor progression and metastasis (  40  ). By means of neutraliz-
ing antibodies, we demonstrated that the activity of IL-8 was 
responsible for macrophage recruitment and for the prometa-
static eff  ect mediated by SEMA3B (  Fig. 7  ). Finally, we identi-
fi  ed the receptor and intracellular pathway, namely NP1 and 
p38  –  MAPK, required to mediate SEMA3B activities in cancer 
(48 h in 1% FCS). Cells treated with 20 nM staurosporin (STS) for 24 h provided a positive control for p21 activation.     -Actin levels provided a reference 
for protein loading. Plotted values indicate fold induction of the p21/    -actin ratio. (F) A549 cells were serum starved for 24 h and then treated for 30 min 
with CM from SEMA3B or EV control cells in the presence of 20 ng/ml anti-NP1 blocking antibody or the unrelated antibody anti  –  VSV-G. Cells treated 
with 20   μ  m cisplatin for 2 h provided a positive control for p38 activation. The levels of phospho-p38 and vinculin (as loading control) were analyzed in 
protein lysates by immunoblotting. (G) Consistent with a previous report, many tumor cells could not survive RNAi-mediated knock down of NP1 (refer-
ence   65  ); however, we managed to stably express NP1-targeted shRNAs (shNP1) in HeLa cells previously transduced with SEMA3B or EV (  Fig. 5 B  ). Real-
time PCR analysis indicated that NP1 expression levels were knocked down to 20% compared with cells transduced with unrelated sequences (shCTR; not 
depicted). Notably, SEMA3B autocrine stimulation was unable to up-regulate IL-8 levels in NP1-defi  cient cells, indicating the requirement for this receptor 
in the signaling pathway. The graph shows fold increase of expression relative to control cells. Data shown are the mean   ±   SEM.   
 
cells, leading to increased expression of IL-8 and the cell-cycle 
inhibitor p21-Waf (  Fig. 8  ). 
  IL-8 is a pleiotropic cytokine produced by tumor cells 
and cells of the tumor microenvironment (  40  –  44  ). IL-8 can 
also act as chemoattractant for neutrophils and monocytes 
(  26  –  28, 35  ). Moreover, it has been shown to promote endo-
thelial cell survival and angiogenesis in vivo, as well as tumor 
cell migration and survival (  42, 43  ). Elevated IL-8 expression 
in tumors is a poor prognostic indicator, correlated with in-
creased metastasis and to remarkable eff  ects on the tumor 
microenvironment (e.g., leukocyte recruitment and tumor 
angiogenesis) (  45, 46  ). Studies have shown that IL-8 levels 
are up-regulated through the activation of p38  –  MAPK and/
or NF-    B independent pathways (  25  ), as well as in response 
to RAS signaling (  34  ). We now show for the fi  rst time that 
SEMA3B induces IL-8 expression in tumor and endothelial 
cells, thereby supporting a new and unexpected function of 
this semaphorin to promote tumor progression and metastasis. 
The specifi  city of SEMA3B-dependent regulation of IL-8 
was confi  rmed in diff  erent ways: (a) SEMA3B overexpression 
in a variety of tumor cells  —  under constitutive or drug-regu-
lated promoters  —  correlated with induced IL-8 levels (  Fig. 5  ); 
(b) RNAi-mediated suppression of endogenous SEMA3B in 
tumor cells led to reduced levels of IL-8 (  Fig. 6  ); and (c) one 
of the two SEMA3B receptors, NP1, was found to be re-
quired for SEMA3B-dependent activation of p38  –  MAPK 
and IL-8 induction (  Fig. 8  ). 
  By means of IL-8-blocking antibodies, we have demon-
strated that the functional diff  erence between SEMA3B-ex-
pressing tumor cells and their respective controls, in terms 
of monocyte/macrophage-attracting activity and metastatic 
progression in vivo, was entirely dependent on the release of 
IL-8 (  Fig. 5 E  ;   Fig. 6 B  ; and   Fig. 7, B and C  ). As expected, 
the CM of tumor cells basally contained additional monocyte 
chemoattractants, independently from SEMA3B regulation. 
This was consistent with our microarray expression analysis; 
moreover, we directly investigated by real-time PCR the 
expression levels of two major monocyte chemoattractants 
capable of mediating invasive/metastatic tumor progression, 
such as CSF-1 and MCP-1, in four diff  erent tumor cell lines 
transduced with SEMA3B. We found that these factors are 
basally expressed; however, unlike what was seen for IL-8, 
there was no consistent induction of MCP-1 or CSF-1 levels 
in cancer cells overexpressing SEMA3B (unpublished data). 
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  Intriguingly, despite the observation that SEMA3B ex-
pression in cancer cells induced high levels of IL-8 and 
increased the recruitment of infi  ltrating macrophages, we 
found that the tumor-associated vessel area was not signifi  -
cantly aff  ected. However, upon IL-8 neutralization, not only 
was SEMA3B-mediated macrophage recruitment inhibited, 
but vessel area was also markedly decreased compared with 
control tumors. These data suggested that IL-8 and the pro-
angiogenic signals released by TAMs in SEMA3B tumors were 
in balance with some antiangiogenic activity. In fact, con-
sistent with what was reported for other class 3 semaphorins 
(  36, 10  –  11  ), we found that SEMA3B is capable of repelling 
HUVECs and inhibiting their migration in vitro, an activity 
that is probably balanced in vivo by the proangiogenic factors 
released by TAMs. Notably, although it was recently shown 
that another semaphorin, SEMA3F, inhibits VEGF expression 
in tumor cells (  52  ), we demonstrated that SEMA3B does 
not aff  ect VEGF levels in cancer cells in vitro or in vivo 
(Fig. S9, available at http://www.jem.org/cgi/content/full/
jem.20072509/DC1). 
  Blood vessels in SEMA3B-expressing tumors further 
revealed defects in pericyte recruitment, a mechanism that 
has been implicated in metastatic dissemination (  53  ). In fact, 
although normal blood vessels get stabilized and remodeled 
by associated pericytes and other   “  mural  ”   cells, pericyte 
from human melanoma samples, we found that SEMA3B 
expression is directly correlated with IL-8 levels and with the 
expression of the macrophage marker CD14 (Fig. S8, available 
at http://www.jem.org/cgi/content/full/jem.20072509/DC1) 
(  47  ). Intriguingly, we did not observe an increased recruit-
ment of neutrophils in SEMA3B-expressing xenografts in vivo, 
although SEMA3B-CM increased the basal migration of 
neutrophils in vitro (by 1.5-fold) because of its content in IL-8 
(unpublished data). This discrepancy may be explained by the 
concept that the recruitment of diff  erent leucocytes into 
growing tumors in vivo is further regulated by the activity of 
additional factors released in the microenvironment by cancer 
and stromal cells. 
  TAMs recruited from the peripheral blood play a crucial 
role in tumor angiogenesis and tumor progression (  24  ), espe-
cially by releasing proangiogenic and proinvasive factors such 
as VEGF or epidermal growth factor (  48  –  51  ). Notably, we 
have evidence in vitro that some of the factors released by 
TAMs, such as epidermal growth factor and VEGF, induce 
the migration of the tumor cells used in our studies (unpub-
lished data). None of these mechanisms is likely to act alone 
to mediate invasion and metastasis in vivo. Thus, we propose 
that the prometastatic function of SEMA3B seen in vivo de-
pends on the activity of IL-8 and on additional factors released 
by macrophages recruited in the tumor microenvironent. 
    Figure 9.         Proposed mechanisms for autocrine SEMA3B signaling in tumor progression.   Schematic diagram depicting our current model to explain 
multiple functional activities of SEMA3B in tumor cells. Autocrine SEMA3B signals, mediated by NP1 receptor (in association with plexins or other receptor 
subunits to be identifi  ed) leads to p38  –  MAPK activation. This results in growth inhibition (via CDKI p21 induction), as well as transcriptional activation of 
IL-8 expression (via ATF-2). In turn, the activity of IL-8 on stromal cells of the tumor microenvironment (including TAM) promotes invasion and metastasis.     JEM VOL. 205, May 12, 2008 
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dence implicates p38  –  MAPK in tumor progression and 
metastasis (for review see reference   57  ) This may be explained 
by a mechanism called   “  tumor dormancy,  ”   by which cancer 
cells slow down proliferation to escape environmental stresses 
while maintaining a high invasive and metastatic potential. 
Consistent with this scenario, SEMA3B-induced p38 activa-
tion may feature an   “  escape  ”   response of tumor cells, based 
on slow cell growth and gene induction promoting invasion and 
metastasis. Interestingly, there are other examples of putative 
tumor suppressors found to promote cancer progression, e.g., 
STAT1 (  58  ) and the SMADs (  59  ). It was also shown that 
hypoxic conditions put a brake on tumor growth, whereas 
they may in turn foster cancer cells that are more aggressive 
and metastatic (  60  ). Moreover, it was recently reported that 
IL-8 induces angiogenesis and rescues tumor cells from under-
going apoptosis in colon cancer cells that lack HIF1-     ex-
pression (  35  ). Notably, although hypoxic conditions have been 
reported to regulate the expression of IL-8 and its receptors 
(  61, 62  ), we detected comparable levels of tissue hypoxia in 
SEMA3B-expressing tumors and in controls (by pimonidazol 
staining; unpublished data). 
  In conclusion, our results indicate that tumors express-
ing high SEMA3B levels grow slowly because of reduced 
proliferation of tumor cells, consistent with our fi  nding that 
SEMA3B induces p38  –  MAPK activation. In addition, SEMA3B 
triggers an escape program from cancer suppression, mediated 
by p38-dependent IL-8 production by tumor cells, and by a 
stromal response that fosters cancer progression and metastatic 
dissemination (  Fig. 9  ).   These unexpected fi  ndings expand our 
knowledge of the functional activities mediated by SEMA3B 
in tumors and suggest a reconsideration of semaphorins as 
multifaceted regulators of cancer progression. 
  MATERIALS AND METHODS 
  Cell lines.     Cell lines were obtained from American Type Culture Collec-
tion, except for the following: GTL-16 (provided by S. Giordano, IRCC, 
Torino, Italy), SUIT-2 (provided by M.F. Di Renzo, IRCC, Torino, Italy), 
and IMR5 (provided by V. Pistoia, Giannina Gaslini Institute, Genoa, Italy). 
Cell lines were grown in standard medium supplemented with   l  -glutamine 
and 10% FBS (Sigma-Aldrich). 
  Antibodies and reagents.     Myc-tagged proteins were detected by a biotin-
conjugated anti-Myc antibody (9E10; Santa Cruz Biotechnology, Inc.). 
Anti-CD31 and anti-F4/80 were purchased from BD Biosciences. Other 
antibodies were as follows: anti  –  VE-cadherin (R  &  D Systems), anti  –  human 
Ki-67 antibody (Dako), anti-NG2 (Chemicon), and anti  –  IL-8 (catalog no. 
MAB208 [clone 6217]; R  &  D Systems). Antibodies to detect p38  –  MAPK, 
phospho-p38 (Thr180/Tyr182), and phospho  –  ATF-2 (Thr71) were from 
obtained from Cell Signaling Technology. Anti-p21 (F-5) was purchased 
from Santa Cruz Biotechnology, Inc., and anti  –  smooth muscle actin was 
purchased from Sigma-Aldrich. Anti-NP1 antibodies (  63  ) were provided by 
A. Kolodkin (Johns Hopkins University, Baltimore, MD). The p38  –  MAPK 
inhibitor SB202190, staurosporin, cisplatin, and any other reagents, if not 
otherwise specifi  ed, were obtained from Sigma-Aldrich. 
  Gene expression in mammalian cells.     Mouse SEMA3B cDNA was 
subcloned, fused with an Myc epitope tag at the C terminus, into the lenti-
viral transfer plasmid pRRLsin.cPPT.hCMV.GFP.Wpre. Nonreplicating 
viral particles containing SEMA3B transfer plasmid (or an EV noncoding 
plasmid as control) were produced in 293T packaging cells and incubated 
  recruitment is often aff  ected in tumor vasculature; endo-
thelial cell survival and morphogenesis thereby becomes de-
pendent on the angiogenic factors released by tumor cells 
and by infi  ltrating TAMs (  54  ). Notably, we found that most 
of the vessels in SEMA3B-expressing tumors were in close 
association with macrophages (  Fig. 7 D  ). In conclusion, the 
metastatic potential of SEMA3B-expressing tumors seems 
to involve multiple coordinated mechanisms dependent 
on IL-8 secretion and on remarkable changes in the tumor 
microenvironment. 
  In our study, we also investigated receptors and signaling 
pathways implicated in SEMA3B-mediated functions in tu-
mor cells. SEMA3B was reported to bind both NP1 and 
NP2. Our unpublished data show that SEMA3B cannot bind 
directly to any of the plexins, whereas several plexins are re-
dundantly capable to associate with NP1 and mediate a func-
tional response to SEMA3B in COS cells similar to that known 
for most secreted class 3 semaphorins (  55  ). We thus focused 
on NPs as required receptors to mediate SEMA3B activity. 
Notably, NPs are widely expressed in cancer cells and in the 
tumor microenvironment (e.g., in endothelial cells). It was 
previously shown that SEMA3B and VEGF have antagonistic 
functions in regulating tumor growth, and this was explained 
by binding competition of the two factors for NP1 (  9  ). We 
have obtained analogous results in A549 cells (unpublished 
data). However recent fi  ndings seem to refute the assumption 
that semaphorin and VEGF binding sites on NP1 are over-
lapping (  56  ). In fact, none of these data ruled out the pos-
sibility that SEMA3B and VEGF may independently elicit 
two antagonistic signaling pathways. In this respect, we have 
demonstrated that NP1 is responsible for SEMA3B-depen-
dent growth inhibition by blunting this eff  ect with NP1 
blocking antibodies (Fig. S3 A). In addition, we showed that 
SEMA3B triggers p38  –  MAPK activation and IL-8 induction 
in an NP1-dependent manner (  Fig. 8, F and G  ). Notably, p38 
signaling is associated with cell-cycle inhibition via the induc-
tion of the CDKI p21 (  37  ), which was also up-regulated in 
response to SEMA3B in our experiments (  Fig. 8 E  ). Thus, 
p38  –  MAPK activation and the consequent induction of the 
CDKI p21 could have a major role in growth inhibition in-
duced by SEMA3B. By using RNAi, we could furthermore 
rule out the requirement of NP2 to mediate SEMA3B func-
tions in tumor cells. For instance, upon RNAi-mediated 
knock down of NP2, the antiproliferatory eff  ect of SEMA3B 
in A549 carcinoma cells was preserved or even increased (Fig. 
S3 B). These data suggest that NP1 and NP2 are alterna-
tive receptors for SEMA3B and trigger independent signal-
ing pathways. 
  We therefore focused on the intracellular mediators lead-
ing to IL-8 induction by SEMA3B in tumor cells. Previous 
data have shown that IL-8 expression is up-regulated through 
the activation of p38  –  MAPK (for review see reference   25  ). In 
this study, we show that p38  –  MAPK activity is signifi  cantly 
induced by SEMA3B; moreover, IL-8 induction was blocked 
by treatment with p38 inhibitors (  Fig. 8  ). Interestingly, in ad-
dition to its role in cell-cycle arrest, a growing body of evi-1168 SEMA3B PROMOTES METASTASIS VIA THE MICROENVIRONMENT | Rolny et al.
tion, the cells were cultured in DMEM supplemented with   l  -glutamine and 
1% FBS for 1, 2, 3, and 4 d. Cells were fi  xed with 11% glutheraldehyde and 
stained with 0.5% crystal violet in 20% methanol. The dye was eluted with 
10% vol/vol glacial acetic acid, and the absorbance at 562 nm was deter-
mined by using a Multiskan reader (Titertek). 
  SDS-PAGE and Western immunoblotting.     Cellular proteins were sol-
ubilized in 1% Triton X-100  –  containing extraction buff  er (20 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 10% glycerol) containing 1 mM Na  3  VO  4  , 
100 mM NaF, 1 mM PMSF, 10   μ  g/ml leupeptin, 10   μ  g/ml aprotinin, and 
1   μ  g/ml pepstatin. The amount of proteins was quantifi  ed by bicinchoninic 
assay, and proteins were separated by SDS-PAGE, transferred to nitrocellu-
lose membranes, and blocked in phosphate-buff  ered saline, 0.1% Tween 20, 
5% BSA. The membrane was incubated with appropriate dilutions of pri-
mary antibody, followed by the appropriate peroxidase-conjugated second-
ary antibody (Bio-Rad Laboratories). Final detection was done by enhanced 
chemiluminescence (GE Healthcare). Detected signals were digitally mea-
sured using QuantityOne (Bio-Rad Laboratories). 
  Monocyte migration assays.     PBMCs were isolated from heparinized 
blood from healthy volunteers by density gradient centrifugation using Lym-
phoprep (Nycomed). Monocytes were positively purifi  ed with a magneti-
cally labeled monoclonal antibody to CD14 (Miltenyi Biotec). Purity of the 
CD14  +   fraction was always   >  94%; contaminating granulocytes were be-
tween 2  –  3%. To test migration, a Transwell system (8-  μ  m pores; Costar) was 
used as previously described (  68  –  70  ). In brief, 2   ×   10  5   monocytes from 
healthy donors were placed in the upper chamber of the insert (in the pres-
ence of 1% FCS) and were allowed to migrate through a semipermeable 
membrane toward CM in the lower chamber. Unless otherwise specifi  ed in 
the fi  gures, we used 10  ×   concentrated CM (containing approximately 60 
ng/ml IL-8; see legend to   Fig. 5 C   for quantifi  cation). When indicated in the 
fi  gures, 0.5  –  1   μ  g/ml anti-IL8 antibody (MAB208), 1   μ  g/ml anti-CD19 con-
trol antibody, or the specifi  ed cytokines were included in the lower chamber. 
After 90 min of migration, cells adherent to the upper side of the membrane 
were mechanically removed. To score for monocyte migration, Transwell 
inserts were fi  xed in methanol, and the cells migrated to the lower side of the 
membrane were stained with Giemsa. By microscopic analysis, we confi  rmed 
that   >  90% of these cells were clearly mononuclear. Low-power microscopic 
images of the Transwell membranes were then analyzed using QuantityOne 
to score the number of migrated cells. Because granulocytes did not adhere 
to the membrane, migrated neutrophils were identifi  ed and counted by fl  ow 
cytometry in the medium from the lower chamber. 
  RNA isolation and real-time PCR.     Total RNA from tumor cell lines 
or tissues was isolated by using the RNeasy Protect Mini Kit (QIAGEN) 
according to the manufacturer  ’  s instructions. cDNA preparation was per-
formed according to standard procedures using M-MLV RT (Promega) and 
oligo-dT (Sigma-Aldrich) primers. The expression of SEMA3B, IL-8, NPs, 
and plexins were analyzed using Taqman gene-specifi  c probes from Applied 
Biosystems (Table S1, available at http://www.jem.org/cgi/content/full/
jem.20072509/DC1). Moreover, we used SYBR green real-time PCR prim-
ers to measure the expression of h-MCP1 (forward, 5    -TCTGTGCCTGCT-
GCTCATAG-3    ; reverse, 5    -GCTTCTTTGGGACACTTGCT-3    ; 168 bp), 
H-CSF-1 (forward, 5    -GCAAGAACTGCAACAACAGC-3    ; reverse, 
5    -CAGAGTCCTCCCAGGTCAAG-3    ; 177 bp), and VEGF-A (forward, 
5    -CCTTGCTGCTCTACCTCCACC-3    ; reverse, 5    -TCCTCCTTCT-
GCCATGGG-3    )  . R  eal-time PCR analysis was performed (7900HT Fast 
Real-time PCR System; Applied Biosystems). 
  RNA extraction and processing for microarray analysis.     Total RNA 
from tumor cell lines was isolated by using RNeasy Protect Mini Kit accord-
ing to the manufacturer  ’  s instructions. RT and biotinylated cRNA synthesis 
were performed using the Illumina TotalPrep RNA Amplifi  cation Kit 
(Ambion), according to the manufacturer  ’  s protocol. Hybridization of the 
cRNAs was performed for 18 h on Human-6 Expression BeadChips (48K 
with cultured human cells in the presence of 8   μ  g/ml polybrene, as previ-
ously described (  64  ). This method ensured stable gene transfer with a very 
high effi   ciency (  >  95% transgene-positive cells, as determined by immuno-
staining), without need to select individual cell clones. In addition, to rule 
out the variability of biological responses, we tested at least three indepen-
dent batches for each construct that was used to transduce cells. Regulated 
expression of SEMA3B was achieved by transducing tumor cells with a 
lentiviral expression construct under the control of an rTTA- and doxycy-
cline-regulated promoter (the cloning plasmid was provided by E. Vigna, 
IRCC, Torino, Italy; reference   65  ). Semaphorin expression was induced 
by adding 0.1  –  1 mg/ml doxycycline in the cell-culture medium, and 1 mg/ml 
in the drinking water of mice. The CM harvested from transduced cells 
grown in the absence of fetal serum were concentrated and size fractionated 
to enrich for SEMA3B and other regulatory proteins using 20 U of Centricon 
Plus (Millipore). 
  Suppression of gene expression by RNAi.     SEMA3B expression was sup-
pressed in tumor cells by lentiviral-mediated expression of shRNAs specifi  -
cally targeting the   SEMA3B   transcript. To this end, we used three diff  erent 
shRNA-SEMA3B sequences with consistent results (Fig. S5): two were 
derived from the Sigma-Aldrich Mission library under accession no. NM_
004636 (sequence 1, TRCN0000062898; and sequence 5, TRCN0000062899), 
whereas the other (sequence 3) was identifi  ed in our laboratory by computer-
assisted analysis (5    -ACGTCCAAGTCTCCGAACA-3    ). Results shown in 
the fi  gures refer to sequence 1. NP1 expression was knocked down by lenti-
viral-mediated expression of gene-targeted shRNA sequences that were pre-
viously described (  66  ), and lentiviral vectors expressing shRNA against NP2 
were provided by S. Rizzolio (IRCC, Torino, Italy). 
  Xenograft tumor model.     All mice studies were conducted with 6  –  8-wk-
old immunocompromised CD1      /      nude athymic female mice (Charles River 
Laboratories. 2   ×   10  6   MDA-MB435 or 10  7   A549 cells were injected subcuta-
neously into the fl  ank of anaesthetized animals. For the treatment with IL-8 
neutralizing antibodies, four groups of fi  ve mice were injected on both sides 
with either MDA-EV or MDA-3B cells, together with 100   μ  g/mouse of ei-
ther IL-8 neutralizing monoclonal antibody (MAB208) or the control anti-
body CD19 (Antigenix America). Tumor size was monitored every 2 d using 
calipers, and the length (l) and width (w) of the developing tumor was con-
verted to volume (v) using the equation v = (w  2     ×   l)/2. Mice were killed 15  –
  30 d after transplant, and tumors were weighted after dissection. Superfi  cial 
pulmonary metastases were contrasted by black India ink airway infusion be-
fore excision, and were counted on dissected lung lobes under a stereoscopic 
microscope, as previously described (  67  ). Histological analysis was performed 
on paraffi   n-embedded sections stained with hematoxylin and eosin. In other 
experiments, lungs were snap frozen in liquid nitrogen for RNA analysis. All 
animal procedures were approved by the Ethical Commission of the Univer-
sity of Torino and by the Italian Ministry of Health. 
  Tissue analysis.     Samples were cut into 10-  μ  m-thick sections and immuno-
stained with the appropriate antibodies. Streptavidin and all secondary anti-
bodies used were conjugated with Alexa Fluor 488 or Alexa Fluor 546 
fl  uorochromes (Invitrogen). Cell nuclei were labeled with DAPI (1:2,000; 
Invitrogen). To detect apoptotic cells in tumor sections, we used an indirect 
TUNEL assay using the ApopTag Green In Situ Apoptosis Detection Kit 
(Chemicon). Slides were mounted with Fluoromount-G (SouthernBio-
tech). Independent fi  elds were quantifi  ed for every section (as indicated 
specifi  cally for each experiment in the corresponding fi  gure legend), and 
diff  erent sections of every tumor (as indicated in the fi  gure legends) were 
analyzed using a microscope (DM IRB; Leica) and quantifi  ed by ImageJ 
software (available at http://rsb.info.nih.gov/ij/). A   t   test was performed for 
all quantifi  cations, and p-values were indicated for each experiment in the 
corresponding fi  gure legend. 
  Growth curve assay.     Tumor cells were plated in multiple 96-well dishes 
(Costar) at an initial density of 10  3   cells per well. After 24 h of serum starva-JEM VOL. 205, May 12, 2008 
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v1.0; Illumina). Hybridized arrays were stained and scanned in a Beadstation 
500 (Illumina) according to the manufacturer  ’  s protocols. 
  Microarray data analysis.     MIAME-compliant microarray data are publicly 
available at the National Center for Biotechnology Information Gene Acces-
sion Omnibus under accession no.   GSE10431  . BeadStudio software (Illumina) 
was used to analyze raw data grouped by experimental condition. After rank-
invariant normalization, genes were fi  ltered for detection (  >  0.95 in at least one 
of the two experimental groups) and assessed for statistically signifi  cant diff  er-
ential expression using the Illumina custom test (iterative robust least squares fi  t). 
To select a panel of genes related to infl  ammation and leukocyte chemotaxis, 
a series of keywords were used to search the Gene Ontology annotation of the 
analyzed probes. The keywords were as follows: interleukin, chemo*, cytokine, 
extracell*, solub*, chemota*, adhesi*, motility, infl  ammat*, and immun*. 
  Online supplemental material.     Fig. S1 shows NP1 and NP2 expression 
in human cancer cells. Fig. S2 shows SEMA3B expression in human tumors. 
Fig. S3 demonstrates that NP1, but not NP2, is required for SEMA3B-me-
diated growth inhibition. Fig. S4 shows that IL-8 stimulates the migration of 
monocytes. Fig. S5 demonstrates that RNAi-mediated knock down of 
endogenous SEMA3B suppresses IL-8 production in tumor cells. Fig. S6 
shows SEMA3B repelling activity on endothelial cells. Fig. S7 demonstrates 
that SEMA3B expression does not increase the formation of lung colonies 
upon tail-vein injection of transduced tumor cells. Fig. S8 shows that SEMA3B 
expression in human melanoma samples correlates with the expression of 
CD14 macrophage marker and elevated IL-8 levels. Fig. S9 demonstrates 
that VEGF expression in tumor cells is not aff  ected by SEMA3B. Sup-
plemental materials and methods describes MTT assays, HUVEC co-culture 
experiments, and endothelial cell migration. Table S1 shows Taqman probes 
used for real-time quantitative PCR. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20072509/DC1. 
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